<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12719">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02941341</url>
  </required_header>
  <id_info>
    <org_study_id>FIN-BEM-2015-01</org_study_id>
    <nct_id>NCT02941341</nct_id>
  </id_info>
  <brief_title>Observational Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Techniques in Spain.</brief_title>
  <acronym>BIRTH</acronym>
  <official_title>Ambispective Observational Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Techniques in Spain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finox AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Finox AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-comparative, observational, ambispective post-authorisation study (EPA-SP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of oocytes retrieved</measure>
    <time_frame>34-36 hours after hCG administration and after a maximum 16 days of r-hFSH treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of fertilised oocytes</measure>
    <time_frame>1 day after ovum pick-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of oocytes</measure>
    <time_frame>At Day 4-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and quality of transferred embryos</measure>
    <time_frame>Day of embryo transfer, either 2,3 or 5 days after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization and implantation rate</measure>
    <time_frame>5 to 6 weeks after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events, including moderate-to-severe OHSS</measure>
    <time_frame>From Day 1 of stimulation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Infertility</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-hFSH</intervention_name>
    <description>As per standard practice</description>
    <other_name>Bemfola</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women who have undergone oocyte retrieval after ovarian stimulation with Bemfola®, either
        as part of an in vitro fertilisation (IVF) cycle or with an intracytoplasmic sperm
        injection (ICSI), for reproductive purposes or for oocyte donation, and who are
        pituitary-suppressed with a GnRH antagonist.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged ≥ 18 years

          -  Currently undergoing an IVF or ICSI cycle or are oocyte-donors

          -  Have completed controlled ovarian stimulation

          -  Have received at least 5 doses of Bemfola®

          -  Are pituitary suppressed with a GnRH antagonist

          -  Have undergone oocyte retrieval

          -  Have signed the Informed Consent Form

        Exclusion Criteria:

          -  Hypersensitivity to the active substance follitropin alfa, FSH or to any of the
             excipients listed

          -  Presence of tumours of the hypothalamus or pituitary gland
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcos Ferrando, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director IVI Bilbao, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Buenaventura Coroleu Lletget, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefe del Servicio de Medicina de la Reproducción,Hospital Universitari Quirón Dexeus, Barcelona, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Rodríguez-Tabernero Martín, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefe de la Unidad de Reproducción, Hospital Clínico Universitario de Valladolid, Valladolid, Spai^n</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mario Gomez</last_name>
    <phone>+34 91 793 80 36</phone>
    <email>mario.gomez@finoxbiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Lopez</last_name>
    <email>c.romera@dynasolutions.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVI Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Asensio, Secretaria de Dirección</last_name>
      <phone>34 93 206 30 00</phone>
      <phone_ext>17542</phone_ext>
      <email>Gina.Asensio@ivi.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 21, 2016</lastchanged_date>
  <firstreceived_date>October 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bemfola</keyword>
  <keyword>r-hFSH</keyword>
  <keyword>ART</keyword>
  <keyword>Oocytes</keyword>
  <keyword>OHSS</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
